How to Source Ziv-aflibercept for Pharmaceutical Formulation

Ziv-aflibercept (Intravenous (IV), 25mg/ml) is classified under Oncology Cancer Care. It is therapeutically aligned with reference brands such as Zaltrap® (US & EU). This guide highlights key sourcing factors buyers should consider when procuring high-quality Ziv-aflibercept for formulation, R&D, or bulk manufacturing.

Product Overview: Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat metastatic colorectal cancer (mCRC) by inhibiting angiogenesis. It targets vascular endothelial growth factor (VEGF), preventing tumor blood vessel growth. Available as an intravenous (IV) injection with a strength of 25 mg/mL, it is used in combination with chemotherapy for mCRC treatment. Ziv-aflibercept is available in both the US and EU, helping improve outcomes for patients with advanced colorectal cancer. Ziv-aflibercept (brand name Zaltrap®) is a recombinant fusion protein used in oncology to treat meta...

1. Regulatory Compliance & Documentation

Ensure suppliers provide:

• ✔ Valid DMF (Drug Master File)
• ✔ COA (Certificate of Analysis) for each batch
• ✔ GMP, ISO, or ICH Q7 compliance certificates

2. Purity, Grade & Specification Matching

Ziv-aflibercept must meet exact grade and purity for your dosage form:

• ✔ USP / EP / JP grade verification
• ✔ Particle size distribution check
• ✔ Residual solvent and heavy metal limits

3. Supplier Reliability & Audit History

• ✔ Positive past audit reports
• ✔ Pharma client references
• ✔ Years of proven API manufacturing experience

4. Commercial Terms: Pricing, MOQ & Flexibility

• ✔ Transparent pricing
• ✔ Pilot batch MOQ flexibility
• ✔ Volume-based discounts

5. Lead Time, Inventory & Logistics

Typical lead time for Ziv-aflibercept is 4–6 weeks.

• ✔ Emergency dispatch options
• ✔ Regional warehousing
• ✔ Special storage if needed

6. Formulation Support

• ✔ Technical datasheets
• ✔ Sample availability
• ✔ Stability study support

Conclusion

Sourcing Ziv-aflibercept is more than procurement—it’s a strategic partnership. With its intravenous (iv) form and 25mg/ml specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.

Frequently Asked Questions For Sourcing of Ziv-aflibercept